Sign in
Not yet taking people in South KoreaPhase 3

Zastaprazan to Prevent Stomach Bleeding in People After Ischemic Stroke or TIA

Tests zastaprazan against placebo for preventing upper gut bleeding after stroke or TIA.

Key facts

Who runs it
Asan Medical Center
Where
Daejeon, Gwangju, Gyeonggi-do, Incheon, Jeju City, Jeonju, and Seoul, South KoreaSee the 15 sites
Trial code
Registry title
Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic Stroke
Status
Not yet recruiting
Phase
Phase 3
People taking part
984 people, planned
Started
15 Oct 2026
Expected to end
30 Sept 2029
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Zastaprazan
  • Placebo
Record updated
9 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who recently had a TIA or ischemic stroke and take antiplatelet or anticoagulant medicine. It tests whether zastaprazan prevents bleeding in the upper digestive tract.

Age
19 years or older
Sex
All sexes can join.
Disease stage
Transient ischemic attack (TIA) or ischemic stroke that began within 180 days before randomization.
Earlier treatment
Must be starting or taking dual antiplatelet therapy (aspirin plus clopidogrel, ticagrelor, prasugrel or cilostazol) or an oral anticoagulant (apixaban, rivaroxaban, dabigatran, edoxaban or warfarin), expected to last at least 3 weeks.

Main reasons for not taking part

  • Peptic ulcer or gastrointestinal bleeding within 1 year, or any past peptic ulcer complication
  • Moderate to severe liver impairment, such as cirrhosis or varices
  • Severe kidney disease needing dialysis, or eGFR below 15
  • Pregnant or breastfeeding women
  • Active bleeding or a blood clotting disorder

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Adults aged 19 years or older
  • Onset of transient ischemic attack (TIA) or ischemic stroke within 180 days prior to randomization
  • Currently initiating or receiving, at the time of randomization, one of the following treatments, with an expected treatment duration of at least 3 weeks:; Dual antiplatelet therapy (DAPT) - aspirin in combination with one of the following: clopidogrel, ticagrelor, prasugrel, or cilostazol B. Oral anticoagulant therapy - a NOAC (apixaban, rivaroxaban, dabigatran, or edoxaban) or warfarin
  • Provision of written informed consent by the participant (or legally authorized representative)

Who cannot take part

  • Clinically significant peptic ulcer or gastrointestinal bleeding within 1 year prior to enrollment
  • Diagnosis of a condition requiring long-term concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs)
  • Currently receiving, or having received within 5 half-lives prior to randomization, a prohibited concomitant medication expected to interact with the investigational product (products containing atazanavir, nelfinavir, or rilpivirine)
  • Moderate to severe hepatic impairment (e.g., diagnosis of cirrhosis or confirmed esophageal/gastric varices)
  • History of major gastrointestinal surgery resulting in malabsorption, bowel obstruction, or inability to take oral medication
  • History of osteoporotic fracture or fragility fracture
  • Diagnosis of a condition requiring long-term, high-dose systemic corticosteroid therapy
  • Life expectancy of less than 6 months due to pre-existing comorbid conditions
  • Any condition that, in the investigator's judgment, precludes participation
  • History of peptic ulcer complications, including bleeding, perforation, or stricture, regardless of timing
  • Active bleeding at the time of enrollment, history of a coagulation disorder, or hemodynamic instability at the time of enrollment
  • Severe thrombocytopenia (platelet count <50,000/µL)
  • End-stage renal disease requiring dialysis, or unstable renal function precluding safe anticoagulant dose adjustment (eGFR <15 mL/min/1.73m²)
  • Known hypersensitivity to potassium-competitive acid blockers (P-CABs) or to the investigational product
  • Known hereditary conditions such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
  • Pregnant or breastfeeding women
  • Current participation in another interventional clinical trial that could affect the results of this study
  • Participant or partner of childbearing/reproductive potential who does not agree to use a medically acceptable method of contraception, or to abstain from sexual activity with risk of pregnancy, during the study period

Where in South Korea

  • Chungnam National University HospitalDaejeon, South KoreaContact: Jong Wook Shin, MD, PhDNot yet recruiting
  • Chonnam National University HospitalGwangju, South KoreaContact: Kang-Ho Choi, MD, PhDNot yet recruiting
  • Ajou University HospitalGyeonggi-do, South KoreaContact: Bum Joon Kim, MD, Ph.D.Not yet recruiting
  • Hallym University HospitalGyeonggi-do, South KoreaContact: Mi Sun OhNot yet recruiting
  • Seoul National University Bundang HospitalGyeonggi-do, South KoreaContact: Beom Joon Kim, MD, PhDNot yet recruiting
  • Uijeongbu Eulji Medical Center, Eulji UniversityGyeonggi-do, South KoreaContact: Dongwhane Lee, MD, PhDNot yet recruiting
  • Catholic Kwandong University International St.Mary's HospitalIncheon, South KoreaContact: Sang Joon An, MD, PhDNot yet recruiting
  • Jeju National University HospitalJeju City, South KoreaContact: Joong Goo Kim, MD, PhDNot yet recruiting
  • jeonbuk National University HospitalJeonju, South KoreaContact: Hyun Goo Kang, MD, PhDNot yet recruiting
  • Asan Medical CenterSeoul, South KoreaContact: Bum Joon Kim, MD, PhDNot yet recruiting
  • Ewha Womans University Seoul HospitalSeoul, South KoreaContact: Tae-Jin Song, MD, PhDNot yet recruiting
  • Korea University Guro HospitalSeoul, South KoreaContact: Chi Kyung Kim, MD, PhDNot yet recruiting
  • Kyung Hee University HospitalSeoul, South KoreaContact: Hogeol Woo, MD, PhDNot yet recruiting
  • Samsung Medical CenterSeoul, South KoreaContact: Hyung Jun Kim, MD, PhDNot yet recruiting
  • Yonsei University Health System, Severance HospitalSeoul, South KoreaContact: JoonNyung Heo, MD, PhDNot yet recruiting

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if zastaprazan can help prevent upper gastrointestinal bleeding in adults who have recently had a transient ischemic attack (TIA) or ischemic stroke and are taking antiplatelet or anticoagulant medications. The main question it aims to answer is:

Read full original descriptionShow less

- Does zastaprazan reduce the risk of upper gastrointestinal bleeding compared to placebo in these patients?

Researchers will compare zastaprazan to a placebo (a look-alike tablet that contains no drug) to see if zastaprazan works to prevent upper gastrointestinal bleeding.

Participants will:

* Take zastaprazan (20 mg) or a placebo once daily for the duration of the study, in addition to their prescribed antiplatelet or anticoagulant medication * Visit the study site regularly for safety monitoring, including vital signs, physical exams, and laboratory tests * Be monitored for any signs of gastrointestinal bleeding or other adverse events for up to approximately 3 years (including screening, treatment, and follow-up periods)

The 2 groups in the trial

  • ZastaprazanTreatment being tested

    Participants will receive zastaprazan citrate 20 mg, administered orally once daily (QD) at a fixed dose, in addition to their prescribed antiplatelet therapy (dual antiplatelet therapy) or oral anticoagulant therapy (NOAC or warfarin).

  • PlaceboPlacebo, for comparison

    Participants will receive a matching placebo for zastaprazan 20 mg, administered orally once daily (QD) at a fixed dose, in addition to their prescribed antiplatelet therapy (dual antiplatelet therapy) or oral anticoagulant therapy (NOAC or warfarin).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-Blind, Placebo-Controlled, Multi-center, Phase 3 Clinical Trial to Evaluate the Efficacy of Zastaprazan in PrEventing Upper Gastrointestinal Bleeding in Patients With Transient Ischemic Attack or Ischemic Stroke Receiving Antiplatelet or Anticoagulant Therapy: ZEUS Trial
Plain-language title
Zastaprazan to Prevent Stomach Bleeding in People After Ischemic Stroke or TIAGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
9 October 2026